Article
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Antimicrobial agents and chemotherapy - 1 Mar 2013
Gottwein Judith M, Jensen Sanne B, Li Yi-Ping, Ghanem Lubna, Scheel Troels K H, Serre Stéphanie B N, Mikkelsen Lotte, Bukh Jens
Abstract excerpt
With the development of directly acting antivirals, hepatitis C virus (HCV) therapy entered a new era. However, rapid selection of resistance mutations necessitates combination therapy. To study combination therapy in infectious culture systems, we aimed at developing HCV semi-full-length (semi-FL) recombinants relying only on the JFH1 NS3 helicase, NS5B, and the 3' untranslated region. With identified adaptive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.